These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32526103)

  • 21. Ondansetron Use in Pregnancy.
    Siminerio LL; Bodnar LM; Venkataramanan R; Caritis SN
    Obstet Gynecol; 2016 May; 127(5):873-877. PubMed ID: 27054931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ondansetron Use in Pregnancy and Birth Defects: A Systematic Review.
    Carstairs SD
    Obstet Gynecol; 2016 May; 127(5):878-883. PubMed ID: 27054939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ondansetron in Pregnancy and the Risk of Congenital Malformations: A Systematic Review.
    Lavecchia M; Chari R; Campbell S; Ross S
    J Obstet Gynaecol Can; 2018 Jul; 40(7):910-918. PubMed ID: 29754832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects.
    Anderka M; Mitchell AA; Louik C; Werler MM; Hernández-Diaz S; Rasmussen SA;
    Birth Defects Res A Clin Mol Teratol; 2012 Jan; 94(1):22-30. PubMed ID: 22102545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ondansetron looks safe in pregnancy, so far.
    BMJ; 2013 Mar; 346():f1387. PubMed ID: 23468289
    [No Abstract]   [Full Text] [Related]  

  • 26. Antiemetic use among pregnant women in the United States: the escalating use of ondansetron.
    Taylor LG; Bird ST; Sahin L; Tassinari MS; Greene P; Reichman ME; Andrade SE; Haffenreffer K; Toh S
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):592-596. PubMed ID: 28220993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Embryo-fetal safety evaluation of ondansetron in rats.
    Reis ACC; Jorge BC; da Silva Moreira S; Stein J; Perdão CB; de Matos Manoel B; Arena AC
    Birth Defects Res; 2023 Apr; 115(6):605-613. PubMed ID: 36737400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ondansetron use during pregnancy: a case series.
    Ferreira E; Gillet M; Lelièvre J; Bussières JF
    J Popul Ther Clin Pharmacol; 2012; 19(1):e1-e10. PubMed ID: 22267256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ondansetron in pregnancy and risk of adverse fetal outcomes.
    Pasternak B; Svanström H; Hviid A
    N Engl J Med; 2013 Feb; 368(9):814-23. PubMed ID: 23445092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect.
    Lemon LS; Bodnar LM; Garrard W; Venkataramanan R; Platt RW; Marroquin OC; Caritis SN
    Int J Epidemiol; 2020 Apr; 49(2):648-656. PubMed ID: 31860078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety considerations surrounding use of treatment options for nausea and vomiting in pregnancy.
    Koren G
    Expert Opin Drug Saf; 2017 Nov; 16(11):1227-1234. PubMed ID: 28749713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new pharmacologic treatment for nausea and vomiting of pregnancy.
    Fantasia HC
    Nurs Womens Health; 2014; 18(1):73-77. PubMed ID: 24548499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Nausea and vomiting in pregnancy: A place for ondansetron?].
    Coulm B
    Gynecol Obstet Fertil Senol; 2021 Dec; 49(12):947-950. PubMed ID: 34700033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treating morning sickness in the United States--changes in prescribing are needed.
    Koren G
    Am J Obstet Gynecol; 2014 Dec; 211(6):602-6. PubMed ID: 25151184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Publishing negative findings and the challenge of avoiding type II errors in studies of suspect teratogens: Example of a recent ondansetron publication.
    Edlavitch SA
    Reprod Toxicol; 2017 Jan; 67():125-128. PubMed ID: 27988282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surviving morning sickness successfully: from patient's perception to rational management.
    Maltepe C
    J Popul Ther Clin Pharmacol; 2014; 21(3):e555-64. PubMed ID: 25654792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-emptive therapy for severe nausea and vomiting of pregnancy and hyperemesis gravidarum.
    Koren G; Maltepe C
    J Obstet Gynaecol; 2004 Aug; 24(5):530-3. PubMed ID: 15369934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy.
    Park JO; Rha SY; Yoo NC; Kim JH; Roh JK; Min JS; Kim BS; Chung HC
    Am J Clin Oncol; 1997 Dec; 20(6):569-72. PubMed ID: 9391542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Major Congenital Malformations Associated With Exposure to Second-Generation Antipsychotic Drugs During Pregnancy.
    Andrade C
    J Clin Psychiatry; 2021 Oct; 82(5):. PubMed ID: 34610230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preventing recurrence of severe morning sickness.
    Koren G; Maltepe C
    Can Fam Physician; 2006 Dec; 52(12):1545-6. PubMed ID: 17279232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.